Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 704 participants.
Also called NCT04523220
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 704 participants
- Sponsor
- Registry
-
NCT04523220 -
2019-003957-27
-
- Other papers using this trial's data
- Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Bulgaria, Czechia, Greece, Hungary, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Portugal, Russia, Spain, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT04523220. Randomized; triple masking; primary purpose treatment. Start 2020-08-28 (actual); primary completion 2021-12-28 (actual). Results posted on 2023-07-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
- Acronym
- CONVERT
- Condition
- End-stage Renal Disease
- Condition
- Prevention of Thromboembolic Events
- Condition
- Hemodialysis
- Condition
- Hemodiafiltration
- Intervention (Drug)
- BAY1213790 (Osocimab)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct04523220- Content hash
891566af7be6cb095c91d4d58deb80a5329a13569525c5e180924a3d894244fe